The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention

Charles E. Mayes, David E. Kandzari, Pascal Goldschmidt-Clermont, Harry R. Phillips

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The percutaneous treatment of symptomatic, obstructive coronary artery disease continues to undergo evolutionary changes that have led to an increase in the number of procedures performed each year. Studies on the adjunctive use of thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors during and following percutaneous coronary intervention (PCI) have demonstrated a reduction in the ischemic complications following PCI. One of the GP IIb/IIIa inhibitors, abciximab, has been shown to reduce mortality 1 year after successful PCI compared with placebo. Despite the reduction in ischemic complications and a potential reduction in mortality at 1 year, the antiplatelet agents have not consistently been shown to affect the rates of restenosis following PCI. Recent, exciting data on the use of drug-eluting stents (DES) in diseased coronary vessels has generated immense enthusiasm within the interventional community about the future ability to dramatically reduce the rates of restenosis following PCI with the use of this novel stent technology. With the introduction and assumed widespread use of these new stents, it appears that the contemporary interventional cardiologist will now have two complementary therapies available for use during percutaneous revascularization: GP IIb/IIIa inhibitors for the reduction of ischemic complications during and immediately following PCI, and DES for the prevention of long- term restenosis within the treated vessel segment. Caution should be taken not to view these valuable therapies as mutually exclusive but rather to recognize that each addresses critical aspects of percutaneous revascularization that have been improved upon after being studied in thousands of patients in controlled, randomized clinical trials.

Original languageEnglish
JournalJournal of Invasive Cardiology
Volume14
Issue number13 SUPPL. E
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Drug-Eluting Stents
Percutaneous Coronary Intervention
Stents
Thienopyridines
Mortality
Platelet Aggregation Inhibitors
Complementary Therapies
Coronary Artery Disease
Coronary Vessels
Randomized Controlled Trials
Placebos
Technology
Therapeutics

Keywords

  • Drug-eluting stent
  • Glycoprotein IIb/IIIa
  • Myocardial ischemia
  • PCI

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. / Mayes, Charles E.; Kandzari, David E.; Goldschmidt-Clermont, Pascal; Phillips, Harry R.

In: Journal of Invasive Cardiology, Vol. 14, No. 13 SUPPL. E, 01.12.2002.

Research output: Contribution to journalArticle

Mayes, Charles E. ; Kandzari, David E. ; Goldschmidt-Clermont, Pascal ; Phillips, Harry R. / The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. In: Journal of Invasive Cardiology. 2002 ; Vol. 14, No. 13 SUPPL. E.
@article{0587d18d22ca463393d2b9c1b974554b,
title = "The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention",
abstract = "The percutaneous treatment of symptomatic, obstructive coronary artery disease continues to undergo evolutionary changes that have led to an increase in the number of procedures performed each year. Studies on the adjunctive use of thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors during and following percutaneous coronary intervention (PCI) have demonstrated a reduction in the ischemic complications following PCI. One of the GP IIb/IIIa inhibitors, abciximab, has been shown to reduce mortality 1 year after successful PCI compared with placebo. Despite the reduction in ischemic complications and a potential reduction in mortality at 1 year, the antiplatelet agents have not consistently been shown to affect the rates of restenosis following PCI. Recent, exciting data on the use of drug-eluting stents (DES) in diseased coronary vessels has generated immense enthusiasm within the interventional community about the future ability to dramatically reduce the rates of restenosis following PCI with the use of this novel stent technology. With the introduction and assumed widespread use of these new stents, it appears that the contemporary interventional cardiologist will now have two complementary therapies available for use during percutaneous revascularization: GP IIb/IIIa inhibitors for the reduction of ischemic complications during and immediately following PCI, and DES for the prevention of long- term restenosis within the treated vessel segment. Caution should be taken not to view these valuable therapies as mutually exclusive but rather to recognize that each addresses critical aspects of percutaneous revascularization that have been improved upon after being studied in thousands of patients in controlled, randomized clinical trials.",
keywords = "Drug-eluting stent, Glycoprotein IIb/IIIa, Myocardial ischemia, PCI",
author = "Mayes, {Charles E.} and Kandzari, {David E.} and Pascal Goldschmidt-Clermont and Phillips, {Harry R.}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "14",
journal = "Journal of Invasive Cardiology",
issn = "1042-3931",
publisher = "HMP Communications",
number = "13 SUPPL. E",

}

TY - JOUR

T1 - The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention

AU - Mayes, Charles E.

AU - Kandzari, David E.

AU - Goldschmidt-Clermont, Pascal

AU - Phillips, Harry R.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The percutaneous treatment of symptomatic, obstructive coronary artery disease continues to undergo evolutionary changes that have led to an increase in the number of procedures performed each year. Studies on the adjunctive use of thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors during and following percutaneous coronary intervention (PCI) have demonstrated a reduction in the ischemic complications following PCI. One of the GP IIb/IIIa inhibitors, abciximab, has been shown to reduce mortality 1 year after successful PCI compared with placebo. Despite the reduction in ischemic complications and a potential reduction in mortality at 1 year, the antiplatelet agents have not consistently been shown to affect the rates of restenosis following PCI. Recent, exciting data on the use of drug-eluting stents (DES) in diseased coronary vessels has generated immense enthusiasm within the interventional community about the future ability to dramatically reduce the rates of restenosis following PCI with the use of this novel stent technology. With the introduction and assumed widespread use of these new stents, it appears that the contemporary interventional cardiologist will now have two complementary therapies available for use during percutaneous revascularization: GP IIb/IIIa inhibitors for the reduction of ischemic complications during and immediately following PCI, and DES for the prevention of long- term restenosis within the treated vessel segment. Caution should be taken not to view these valuable therapies as mutually exclusive but rather to recognize that each addresses critical aspects of percutaneous revascularization that have been improved upon after being studied in thousands of patients in controlled, randomized clinical trials.

AB - The percutaneous treatment of symptomatic, obstructive coronary artery disease continues to undergo evolutionary changes that have led to an increase in the number of procedures performed each year. Studies on the adjunctive use of thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors during and following percutaneous coronary intervention (PCI) have demonstrated a reduction in the ischemic complications following PCI. One of the GP IIb/IIIa inhibitors, abciximab, has been shown to reduce mortality 1 year after successful PCI compared with placebo. Despite the reduction in ischemic complications and a potential reduction in mortality at 1 year, the antiplatelet agents have not consistently been shown to affect the rates of restenosis following PCI. Recent, exciting data on the use of drug-eluting stents (DES) in diseased coronary vessels has generated immense enthusiasm within the interventional community about the future ability to dramatically reduce the rates of restenosis following PCI with the use of this novel stent technology. With the introduction and assumed widespread use of these new stents, it appears that the contemporary interventional cardiologist will now have two complementary therapies available for use during percutaneous revascularization: GP IIb/IIIa inhibitors for the reduction of ischemic complications during and immediately following PCI, and DES for the prevention of long- term restenosis within the treated vessel segment. Caution should be taken not to view these valuable therapies as mutually exclusive but rather to recognize that each addresses critical aspects of percutaneous revascularization that have been improved upon after being studied in thousands of patients in controlled, randomized clinical trials.

KW - Drug-eluting stent

KW - Glycoprotein IIb/IIIa

KW - Myocardial ischemia

KW - PCI

UR - http://www.scopus.com/inward/record.url?scp=0036920162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036920162&partnerID=8YFLogxK

M3 - Article

C2 - 12668861

AN - SCOPUS:0036920162

VL - 14

JO - Journal of Invasive Cardiology

JF - Journal of Invasive Cardiology

SN - 1042-3931

IS - 13 SUPPL. E

ER -